Search
M0002
go.drugbank.com/drugs/DB05091InvestigationalM0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.
Deleobuvir
go.drugbank.com/drugs/DB14850InvestigationalDeleobuvir is under investigation in clinical trial NCT01983566 (Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects
Ilacirnon
go.drugbank.com/drugs/DB16066InvestigationalIlacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).
Synonyms: 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamidePenimepicycline
go.drugbank.com/drugs/DB13264ExperimentalIn the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans [L5620]. … It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalIn November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.
Loteprednol etabonate
go.drugbank.com/drugs/DB14596ApprovedIt is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes
ONO-2952
go.drugbank.com/drugs/DB14802InvestigationalONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable
Rineterkib
go.drugbank.com/drugs/DB17560InvestigationalRuxolitinib Combinations in Myelofibrosis Patients). … Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel
Synonyms: 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluorobenzamide, Benzamide, 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluoro-Velafermin
go.drugbank.com/drugs/DB06493Investigationalactivity in multiple animal models. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated
Serabelisib
go.drugbank.com/drugs/DB14935Investigationalof TAK-117 (MLN1117) in Healthy Participants). … Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics